| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7–IFCT-1402): a multicentre, randomised, controlled phase 2 trial
|
Vera, Pierre
|
|
|
25 |
9 |
p. 1176-1187
|
artikel
|
| 2 |
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
|
Bührer, Emanuel
|
|
|
25 |
9 |
p. 1202-1212
|
artikel
|
| 3 |
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Colombo, Nicoletta
|
|
|
25 |
9 |
p. 1135-1146
|
artikel
|
| 4 |
Cancer incidence and survival for 11 cancers in the Commonwealth: a simulation-based modelling study
|
Ward, Zachary J
|
|
|
25 |
9 |
p. 1127-1134
|
artikel
|
| 5 |
Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial
|
Oliveira, Mafalda
|
|
|
25 |
9 |
p. 1231-1244
|
artikel
|
| 6 |
Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup
|
Creutzberg, Carien L
|
|
|
25 |
9 |
p. e420-e431
|
artikel
|
| 7 |
Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study
|
Karpinski, Madeleine J
|
|
|
25 |
9 |
p. 1188-1201
|
artikel
|
| 8 |
Completion axillary lymph node dissection for the identification of pN2–3 status as an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial
|
de Boniface, Jana
|
|
|
25 |
9 |
p. 1222-1230
|
artikel
|
| 9 |
Contextualising legal and ethical conundrums of artificial intelligence in oncology
|
Zakout, Ghada
|
|
|
25 |
9 |
p. 1113-1116
|
artikel
|
| 10 |
Correction to Lancet Oncol 2023; 24: 733–43
|
|
|
|
25 |
9 |
p. e401
|
artikel
|
| 11 |
Defining the quality of interdisciplinary care for patients with brain metastases: modified Delphi panel recommendations
|
Fadul, Camilo E
|
|
|
25 |
9 |
p. e432-e440
|
artikel
|
| 12 |
Disappointment facing patients with breast cancer as trastuzumab deruxtecan too expensive for NHS
|
Gourd, Elizabeth
|
|
|
25 |
9 |
p. 1122
|
artikel
|
| 13 |
Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trial
|
Blay, Jean-Yves
|
|
|
25 |
9 |
p. 1163-1175
|
artikel
|
| 14 |
Ending financial discrimination for cancer survivors: embedding the Right to be Forgotten in legislation across Europe
|
Lawler, Mark
|
|
|
25 |
9 |
p. 1123-1126
|
artikel
|
| 15 |
Enhancing cardiovascular disease risk management in childhood cancer survivors
|
Yang, Lan
|
|
|
25 |
9 |
p. e399
|
artikel
|
| 16 |
Enhancing cardiovascular disease risk management in childhood cancer survivors
|
Liu, Fei
|
|
|
25 |
9 |
p. e400
|
artikel
|
| 17 |
Enhancing equity and long-term impact assessments in radiotherapy environmental studies
|
Li, Xiang
|
|
|
25 |
9 |
p. e397
|
artikel
|
| 18 |
Enhancing equity and long-term impact assessments in radiotherapy environmental studies
|
Yang, Guang
|
|
|
25 |
9 |
p. e398
|
artikel
|
| 19 |
Imatinib in advanced GIST: if it's working, don’t stop a good thing
|
Denu, Ryan A
|
|
|
25 |
9 |
p. 1105-1107
|
artikel
|
| 20 |
Improving cancer control initiatives in Indigenous people
|
Gruber, Karl
|
|
|
25 |
9 |
p. 1117-1118
|
artikel
|
| 21 |
Improving individualised therapies in localised gastro-oesophageal adenocarcinoma
|
Svrcek, Magali
|
|
|
25 |
9 |
p. e452-e463
|
artikel
|
| 22 |
Legacies of conflict and humanitarian crises on cancer care
|
The Lancet Oncology,
|
|
|
25 |
9 |
p. 1103
|
artikel
|
| 23 |
Measuring success of adjuvant treatment for patients with melanoma
|
O'Carrigan, Brent
|
|
|
25 |
9 |
p. 1109-1110
|
artikel
|
| 24 |
Multimodality imaging of a large incidental papillary fibroelastoma
|
Elkhatib, Wiaam
|
|
|
25 |
9 |
p. e464
|
artikel
|
| 25 |
New immigration laws could undermine cancer research in the UK
|
Gruber, Karl
|
|
|
25 |
9 |
p. 1121
|
artikel
|
| 26 |
Over US$100 million pledged to improve cancer care across Africa
|
Adepoju, Paul
|
|
|
25 |
9 |
p. 1119
|
artikel
|
| 27 |
Peru advances towards universal health care for patients with cancer
|
Burki, Talha
|
|
|
25 |
9 |
p. e402
|
artikel
|
| 28 |
Poor progress on reducing alcohol consumption in Europe
|
Burki, Talha
|
|
|
25 |
9 |
p. 1120
|
artikel
|
| 29 |
Postoperative radiotherapy in women with early operable breast cancer (Scottish Breast Conservation Trial): 30-year update of a randomised, controlled, phase 3 trial
|
Williams, Linda J
|
|
|
25 |
9 |
p. 1213-1221
|
artikel
|
| 30 |
Progress in NCD screening in Mongolia
|
Devi, Sharmila
|
|
|
25 |
9 |
p. e403
|
artikel
|
| 31 |
The oncological role of resection in newly diagnosed diffuse adult-type glioma defined by the WHO 2021 classification: a Review by the RANO resect group
|
Karschnia, Philipp
|
|
|
25 |
9 |
p. e404-e419
|
artikel
|
| 32 |
Time to abandon axillary lymph node dissection in early-stage breast cancer
|
Barrio, Andrea V
|
|
|
25 |
9 |
p. 1111-1113
|
artikel
|
| 33 |
Translating the theranostic concept to neuro-oncology: disrupting barriers
|
Albert, Nathalie L
|
|
|
25 |
9 |
p. e441-e451
|
artikel
|
| 34 |
Trastuzumab deruxtecan in HER2-positive metastatic colorectal cancer: less is more?
|
Roodhart, Jeanine M L
|
|
|
25 |
9 |
p. 1104-1105
|
artikel
|
| 35 |
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial
|
Raghav, Kanwal
|
|
|
25 |
9 |
p. 1147-1162
|
artikel
|
| 36 |
Use of PROMISE criteria on PSMA-PET for prediction of overall survival in prostate cancer
|
Bouchelouche, Kirsten
|
|
|
25 |
9 |
p. 1107-1108
|
artikel
|
| 37 |
Who does not benefit from whole-breast radiotherapy and how to find them?
|
Kolberg, Hans-Christian
|
|
|
25 |
9 |
p. 1110-1111
|
artikel
|
Tijdschrift beschrijving